B-Lymphoblastic Leukemia (B-ALL) Minimum Residual Disease Detection by Flow Cytometry
Also known as: B-ALL MRD
Use
The B-Lymphoblastic Leukemia (B-ALL) Minimum Residual Disease Detection test is used to detect minimal residual disease (MRD) in patients of all ages who have been previously diagnosed with B-ALL. It provides insights into the presence of residual cancerous cells post-treatment. The specific markers used and reported vary based on the specimen submitted and whether a Children's Oncology Group (COG) protocol is specified at the time of ordering.
Special Instructions
Orders for whole blood testing will be canceled if the patient is 31 years or older or if there is a prior history of COG whole blood testing. Submit prior diagnostic immunophenotyping studies if available, as they may help in the assessment of post-treatment specimens.
Limitations
The test has limited sensitivity due to low specimen viability, and the stability of the sample rapidly decreases after collection, requiring the specimen to be received within 24 hours. The limit of detection for B-ALL blasts is approximately 0.01% of mononuclear cells.
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 19099-1
- 45267-2
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
1.0 mL
Container
green (sodium heparin) or lavender (EDTA)
Storage Instructions
Room temperature. Also acceptable: Refrigerated.
Causes for Rejection
Clotted or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 48 hours |
| Frozen | Unacceptable |